Nurix Therapeutics Inc
For the period ended Nov 30, 2024. Filed Jan 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jan 28, 2025
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||||
| Balance as of November 30, 2021 | 44,664,371 | $45 | $563,757 | $(608) | $(220,892) | $342,302 | ||||||
| Issuance of pre-funded warrants, net of issuance costs of $234 | — | — | 94,759 | — | — | 94,759 | ||||||
| Issuance of common stock in "at the market" financing, net of issuance costs of $672 | 2,000,000 | 2 | 19,326 | — | — | 19,328 | ||||||
| Exercise of stock options | 325,596 | — | 1,078 | — | — | 1,078 | ||||||
| Vesting of restricted stock units | 46,028 | — | — | — | — | — | ||||||
| Vesting of early exercised stock options | — | — | 145 | — | — | 145 | ||||||
| Issuance under employee stock purchase plan | 136,304 | — | 1,955 | — | — | 1,955 | ||||||
| Stock-based compensation | — | — | 28,200 | — | — | 28,200 | ||||||
| Unrealized loss on available-for-sale marketable securities | — | — | — | (3,711) | — | (3,711) | ||||||
| Net loss | — | — | — | — | (180,360) | (180,360) | ||||||
| Balance as of November 30, 2022 | 47,172,299 | 47 | 709,220 | (4,319) | (401,252) | 303,696 | ||||||
| Exercise of pre-funded warrants | 717,360 | 2 | — | — | — | 2 | ||||||
| Exercise of stock options | 120,826 | — | 986 | — | — | 986 | ||||||
| Vesting of restricted stock units | 441,103 | — | — | — | — | — | ||||||
| Vesting of early exercised stock options | — | — | 117 | — | — | 117 | ||||||
| Issuance under employee stock purchase plan | 266,964 | — | 2,229 | — | — | 2,229 | ||||||
| Stock-based compensation | — | — | 33,747 | — | — | 33,747 | ||||||
| Unrealized gain on available-for-sale marketable securities | — | — | — | 3,664 | — | 3,664 | ||||||
| Net loss | — | — | — | — | (143,948) | (143,948) | ||||||
| Balance as of November 30, 2023 | 48,718,552 | $49 | $746,299 | $(655) | $(545,200) | $200,493 | ||||||
| Issuance of common stock and pre-funded warrants, net of issuance costs of $12,518 | 11,916,667 | 12 | 188,720 | — | — | 188,732 | ||||||
| Issuance of common stock in "at the market" financing, net of issuance costs of $6,186 | 13,777,775 | 14 | 289,355 | — | — | 289,369 | ||||||
| Exercise of pre-funded warrants | 19,750 | — | — | — | — | — | ||||||
| Exercise of stock options | 508,648 | 1 | 5,054 | — | — | 5,055 | ||||||
| Vesting of restricted stock units | 654,396 | — | — | — | — | — | ||||||
| Vesting of early exercised stock options | — | — | 33 | — | — | 33 | ||||||
| Repurchase of unvested early exercised stock | (1,548) | — | — | — | — | — | ||||||
| Issuance under employee stock purchase plan | 276,478 | — | 2,132 | — | — | 2,132 | ||||||
| Stock-based compensation | — | — | 33,943 | — | — | 33,943 | ||||||
| Unrealized gain on available-for-sale marketable securities | — | — | — | 805 | — | 805 | ||||||
| Net loss | — | — | — | — | (193,569) | (193,569) | ||||||
| Balance as of November 30, 2024 | 75,870,718 | $76 | $1,265,536 | $150 | $(738,769) | $526,993 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.